Signifor
Phase 2Small molecule
Signifor is one of 5 small molecule programs targeting Desmoplastic Small Round Cell Tumor. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Desmoplastic Small Round Cell Tumor
#DrugCompanyPhaseTrials
1Camptosar
PfizerPhase 2
Zepzelca
Jazz PharmaceuticalsPhase 2
Herceptin
OOrganon and Co
Phase 2
Trastuzumab Deruxtecan
AstraZenecaPhase 2
Signifor
ZZealand University Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Signifor. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZealand University Hospital